FDA Requires Manufacturers to Provide Mail-Back Envelopes for Opioid Disposal
Approval of the modified Opioid Analgesic REMS is expected in 2024.
Approval of the modified Opioid Analgesic REMS is expected in 2024.
Lauren McDermott, a patient living with atypical SPS, shares her journey from receiving an official diagnosis to the treatments that help her manage her condition.
Increased demand for ibuprofen oral suspension products due to a surge in 3 circulating viruses prompted the Agency to issue compounding guidance.
It was originally approved in 2019 for the treatment of chronic pain.
Zavzpret (zavegepant) nasal spray is a calcitonin gene-related peptide (CGRP) receptor antagonist.
To better understand the new phenomenon of “patient influencers”, the authors conducted interviews with individuals who routinely offer advice on health topics on social media.
The product was designed using the Amphastar’s proprietary nasal delivery device.
In 2011, following reports of serious livery injury, the FDA had required manufacturers of prescription acetaminophen combination products to limit the amount of acetaminophen to 325mg per tablet or capsule.
Elyxyb is a ready-to-use oral solution formulation of celecoxib, a nonsteroidal anti-inflammatory drug.
In a cross-sectional study, researchers addressed whether medical cannabis is changing the use of other pain treatments among adults with noncancer chronic pain.